



(11) **EP 2 546 651 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
16.01.2013 Bulletin 2013/03

(51) Int Cl.:
G01N 33/50 (2006.01) **A61P 35/00** (2006.01)
C12Q 1/68 (2006.01) **C12N 15/113** (2010.01)
C12N 15/11 (2006.01)

(21) Application number: **12179806.0**

(22) Date of filing: **14.03.2008**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**
Designated Extension States:
AL BA MK RS

(72) Inventors:
• **Lavitrano, Marialuisa.**
I-20129 Milano (IT)
• **Grassilli, Emanuela.**
I-20052 Monza (IT)
• **Helin, Kristian.**
DK-2920 Charlottenlund (DK)

(30) Priority: **14.03.2007 IT PD20070088**
13.04.2007 EP 07106119

(74) Representative: **Zaccaro, Elisabetta et al**
Notarbartolo & Gervasi S.p.A.
Corso di Porta Vittoria, 9
20122 Milano (IT)

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
08717840.6 / 2 134 374

(71) Applicant: **Bionsil S.r.l.**
20123 Milano (IT)

Remarks:

This application was filed on 09-08-2012 as a
divisional application to the application mentioned
under INID code 62.

(54) **Modulator compounds of the drug resistance in epithelial tumour cells**

(57) The use of compounds is described which are capable of functionally blocking at least one of the genes chosen from the group composed of EphA1, EphA2, EphA8, EphB2, CSF1R, VEGFR2, RAMP2, RAMP3, CLRN1, MAPK4, PIK3C2A, PIK3CG, GSK3alpha, GSK3beta, IRAK3, DAPK1, JAK1, PIM1, TRB3, BTG1, LATS1, LIMK2, MYLK, PAK1, PAK2, CDC2, BTK, PNRC2, NCOA4, NR2C1, TPR, RBBP8, TRPC7,

FXD1, ERN1, PRSS16, RPS3, CCL23 and SERPINE1, for the manufacture of a medicament destined to diminish the resistance to chemotherapeutic drugs in the therapeutic treatment of epithelial tumour pathologies. Also described is a method for the determination of the drug resistance in tumour cells, as well as a method for the identification of tumour stem cells.

Description**Technical Field**

5 **[0001]** The present invention regards the use of compounds for the production of a medicament capable of modulating, and in particular diminishing the drug resistance in human epithelial tumour cells, according to the characteristics stated in the preamble of the main claim. It is also intended for a determination method of the drug resistance in tumour cells as well as a method for the identification of tumour stem cells.

10 **Technological Background**

[0002] One of the most commonly followed strategies in the therapy of neoplastic pathologies foresees the use of drugs (chemotherapy) capable of damaging the DNA of the tumour cells, so as to induce the natural process of apoptosis in the same.

15 **[0003]** Nevertheless, it is known that the tumour cells may respond in an unexpected manner to the drug therapy, showing, on the contrary, a strong resistance to the same. It is also known that one of the main reasons for the drug resistance shown by the tumour cells is the incapacity of the cells to begin the process of apoptosis, even in the presence of considerable DNA damage.

20 **[0004]** This phenomenon was traced back to a functional alteration (mutation or deletion) of the gene p53, which is no longer capable of initiating the process of cellular apoptosis, thus leading the cells to resist the drug action. The drug resistance levels of the tumour cells can be very high. For example, in the case of tumour cells of the colon-rectum in advanced phase, a drug therapy based on 5-fluorouracil (5FU) shows an effective response only for 10-15% of the cells, and a combination of 5FU with new drugs such as irinotecan and oxaliplatin leads to an increase of the cell mortality up to 40-50%, a value which is still entirely unsatisfactory for an effective therapeutic action towards the neoplastic pathologies.

25 **[0005]** In recent years, a cell phenomenon was discovered called "RNA interference" (RNAi) by means of which the gene expression is silenced in a specific manner. By taking advantage of such process, it is possible to obtain the selective silencing of genes with unknown function, thus permitting the definition of its specific function through the study of the obtained phenotype. By applying RNAi techniques and studying the phenotypic results, it is moreover possible to assign new functions to already known genes.

30 **[0006]** The genes involved in the phenomenon of drug resistance of the tumour cells are today largely unknown.

[0007] There is very much the need, therefore, to identify new genes involved in the drug-resistance and to design methods and compounds capable of substantially diminishing the tumour cells' resistance to drugs.

35 **Description of the invention**

[0008] The problem underlying the present invention is that of making available compounds capable of reducing the drug resistance of the tumour cells of epithelial type, in order to permit the manufacture of medicaments destined for the therapy of related neoplastic pathologies.

40 **[0009]** This problem is resolved by the present finding by means of the use of compounds capable of functionally blocking one or more genes chosen from the group identified in the attached claims.

[0010] In a second aspect thereof, this invention moreover provides a method for the determination of the drug resistance of epithelial tumour cell lines.

45 **[0011]** In a further aspect thereof, this invention moreover provides a method for the identification of tumour stem cells.

Brief description of the drawings

[0012] The characteristics and advantages of the invention will be clearer from the detailed description which follows of the tests and results which have led to its definition, reported with reference to the drawing set wherein :

- 50
- Figure 1 is a graph illustrating the results of inhibition of the capacity to form drug-resistant tumour cell colonies of the colon treated with the compounds according to the invention and a chemotherapeutic drug,
 - Figures 2a and 2b are graphs showing the results of an analysis of reversion of the resistance of a tumour cell line to two different chemotherapeutic drugs by means of silencing of the alpha and beta isoforms of the gene GSK3,
 - 55 - Figures 3a - 3c are graphs illustrating the results of the tests of reversion of the resistance to a chemotherapeutic drug of three different tumour cell lines of the colon by means of silencing of the gene GSK3beta,
 - Figure 4a is a graph illustrating the results of the tests of reversion of the resistance to a different chemotherapeutic drug of two different tumour cell lines of the colon by means of silencing of the gene GSK3beta,

EP 2 546 651 A1

- Figure 4b is a graph illustrating the results of an analysis of reversion of the resistance of a tumour cell line to the combination of two different chemotherapeutic drugs by means of the silencing of the beta isoform of the gene GSK3,
- Figure 5 is a collection of images illustrating the location of cytochrome C for 5FU-induced cell death in the absence of GSK3.
- 5 - Figure 6 a graph illustrating the results of caspase 3 and caspase 7 activation assays in response to 5FU treatment of HCT1 16 and GSK3alpha, GSK3beta gene silenced HCT116p53KO colon carcinoma cells,
- Figure 7 is a collection of images illustrating the translocation of AIF to the nucleus during 5FU-induced cell death in the absence of GSK3,
- Figure 8 is a graph illustrating the reversion of the resistance to a chemotherapeutic drug of a tumour cell line carried out by means of functional blocking of the gene BTK obtained with different methods,
- 10 - Figure 9 is a graph illustrating the percentage of cell death induced by 5FU upon BTK overexpression in HCT116 colon carcinoma cells,
- Figures 10a and 10b are graphs illustrating the reversion of the resistance to chemotherapeutic drugs by means of the functional blocking of the gene BTK on different colon tumour cell lines,
- 15 - Figure 11 is a western blot analysis showing BTK expression in several tumoral cell lines derived from different epithelial cancers,
- Figures 12a and 12b are graphs illustrating the reversion of the resistance to chemotherapeutic drugs by means of the functional blocking of the gene BTK on epithelial tumour cell lines other than colon,
- Figure 13 is collection of images illustrating the cytoplasmic accumulation of cytochrome C in 5FU-treated cells upon BTK inhibition,
- 20 - Figure 14 is a graph illustrating the results of fluorimetric caspase activation assays after 72 hrs and 96 hrs in HCT1 16 and HCT116p53KO colon carcinoma cells treated with 5FU, BTK inhibition, or the combination of the two,
- Figure 15a is western blot image showing that antibody sc-1696 specifically recognizes BTK protein and that in epithelial carcinoma cells (HCT116p53KO) BTK has an apparent molecular weight of ~67 kDa and that the same form of the protein is present, together with the "classic" 77 kDa form, also in leukemic cells (Nalm6),
- 25 - Figure 15b is an immunoprecipitation-western blot image confirming that also a different antibody (BL7) identify BTK protein as being ~67 kDa in HCT116p53KO cells and that this isoform is present in leukemic cells (Nalm6) together with the "classic" 77 kDa form,
- Figure 16 is an image illustrating the results of a PCR experiment showing that the 5' end upstream of nucleotide 202 in the BTK- encoding mRNA from HCT116p53KO cells is absent or different from the 5' end of BTK mRNA from peripheral blood mononuclear cells (PBMC),
- 30 - Figure 17 is an image illustrating the results of ClustalW alignment of BTK transcript, identified by GenBank Accession #NM_000061, and the novel transcript identified in HCT116p53KO cells by 5'RACE PCR followed by cloning and sequencing (indicated as alternative), the box outlining the part of BTK sequence (starting from nucleotide 131 of the known transcript) common between BTK mRNA deriving from #NM_000061 and the novel BTK transcript found in HCT116p53KO,
- 35 - Figure 18 is an image illustrating the results of a Blast alignment vs a genomic database of exons 1-5 of BTK transcript identified by GenBank Accession # NM_000061 and the same exons of the novel BTK transcript, the dots indicating the position on chromosome X of the different exons of BTK,
- 40 - Figure 19 is an image illustrating the results of a nested PCR experiment showing that the novel BTK transcript is expressed in Formalin-Fixed Paraffin-Embedded (FFPE) tumoral tissues from coloncarcinoma patients.

Identification methodology of the genes modulating the drug resistance in epithelial tumour cells and related validation tests

- 45
- [0013]** The abovementioned technical problem was tackled by subjecting several epithelial tumour cell lines to a series of tests and analyses geared to identify and characterise the genes capable of giving rise to the phenotypic expression of interest, i.e. the reversion of the resistance to the apoptosis induced by chemotherapeutic drugs.
- [0014]** Such identification was conducted by means of phenotypic screening of a representative cell line of the epithelial tumour cells following the selective silencing of an extended group of genes by means of RNAi.
- 50
- [0015]** This complex screening work was made possible due to a library of retroviral pRetroSuper (pRS) vectors recently made by the Bernards laboratories. It is known that such vectors are capable of expressing a specific oligonucleotide molecule in a stable manner, known as small interference RNA, in brief siRNA, capable of blocking the translation process of a specific messenger RNA (mRNA) in the corresponding protein. Such mechanism, in brief, foresees that the siRNA molecule (or rather a filament thereof) is associated with the RISC enzymatic complex, activating it, such that the latter can recognise and bind to the mRNA complementary to the siRNA associated thereto and then degrade it. It follows that the mRNA, identified in a specific manner by the siRNA, cannot be translated in the corresponding amino acid chain, thus obtaining the silencing of the gene from which the mRNA was transcribed. The interference process is
- 55

specific, so that a siRNA molecule is normally capable of degrading only one mRNA and therefore silencing one single gene. On the other hand, it is instead possible that the same mRNA can be degraded, via RISC, by different siRNA.

[0016] This mechanism is one of the different possible modes for functionally blocking a gene (functional knockout). However, the consequent degradation of siRNA via RISC produces only a transient effect on protein levels, thus allowing only short term experiments whose results may be not relevant in the long term. To overcome this problem, short hairpin RNAs (shRNAs), a sequence of RNA folded in the shape of a hairpin, were used as a mechanism for functional knockout. In brief, a vector is used to introduce and incorporate shRNA into the cell chromosome. Transcription of the DNA produces shRNA which is subsequently cleaved by the cellular machinery, DICER, into siRNA. The siRNA then functions as previously mentioned. The incorporation of the shRNA vector into the cell chromosome allows for the gene silencing to be inherited by daughter cells. Thus the usage of shRNAs allows for functional knock out cells that can be used for long term experiments.

[0017] It is also known in the literature that the efficiency of transfection for siRNAs is never 100%. Therefore, the use of transfected siRNAs does not assure that all treated cells are successfully deprived of a target protein. The absence of a selectable marker further creates a problem in working with homogeneous populations of cells. Using a selectable marker, such as a puromycin resistance gene, along with a retroviral library, allows for recovery of only the cells bearing shRNAs. Moreover, following shRNA expression selection, only genes whose silencing is compatible with normal cell survival and proliferation are selected for. The absence of these genes does not influence normal cell physiology but only the response to anticancer drugs, a very important consideration while developing anticancer therapy.

[0018] It is nevertheless important to specify that the same effect can, in general, be reached by acting in any other step of a gene's protein coding process, such as for example the step of transcription of the gene in mRNA, or the step of mRNA transduction, or by means of inhibition of the protein resulting from the coding process.

[0019] It is evident that the essential and critical step in the resolution of the problem is represented by the identification of the responsible gene or genes of the desired phenotype. The retroviral library arranged by the Bernards laboratories consists of about 25,000 different elements, capable of silencing about 8,300 genes of the human genome, with a ratio of about 3 different vectors for each gene.

[0020] The tests were initially conducted in vitro and subsequently validated ex vivo on different epithelial tumour cell lines, characterised by the lack of or by the mutation of the gene p53 and hence provided with a marked resistance to chemotherapeutic drugs.

[0021] In detail, a human RNAi library (NKi library) was established, consisting of 8,300 targeted genes for silencing. The targeted genes included kinases, phosphatases, oncogenes, tumor suppressors, transcription factors, genes involved in transformation, metastasis, cell cycle, differentiation, apoptosis, metabolic and anabolic processes. A protocol was followed similar to that mentioned in a prior publication (Berns et al., NATURE vol. 428, 25 March 2004). The contents of this publication are incorporated by reference into this application. The mRNA sequence for each targeted gene was selected from UniGene. The sequences were masked using RepeatMasker to remove repetitive sequences and searched with NCBI BLAST against UniVec to mask for vector contamination. Three different 19 nucleotide (19-mer) sequences for silencing each targeted gene were designed, for a total of approximately 25,000 59-mer oligonucleotides that specify short hairpin RNAs (shRNAs). The 19-mer sequences were selected using a selection criteria as mentioned in the Berns publication wherein, a) there were no stretches of four or more consecutive T or A residues (to avoid premature polymerase III transcription termination signals); b) to have 30-70% overall GC content; c) to lie within the coding sequence of the target gene; d) to begin with a G or C residue (consistent with recently established rules for strand bias); e) to begin after an AA dimer in the 5' flanking sequence; f) to end just prior to a TT, TG or GT doublet in the 3' flanking sequence; g) to not contain XhoI or EcoRI restriction enzyme sites to facilitate subsequent shuttling of the knockdown cassette into vector backbones; h) to share minimal sequence identity with other genes; i) to target all transcript variants represented by RefSeq mRNAs; and j) to not overlap with other 19-mers selected from the same target sequence. The 59-mer oligonucleotides were designed as to contain a 19-mer sequence, its complimentary 19-mer sequence, polIII transcription initiation site, polIII termination site, and HindIII/BglII cloning sites. Utilizing the HindIII/BglII cloning sites, the oligonucleotides were ligated into pRetroSuper (pRS) retroviral vectors, which included a selection cassette for puromycin resistance. The DNA from the three different vectors that targeted the same gene was pooled and virus was produced to infect target cells.

EXAMPLE 1

[0022] The tumour cell line initially used was HCT116p53KO (which differs from the wild type wt HCT116 due to the lack of gene p53), related to the colon tumour, while further detailed studies of specific genes were carried out on other drug-resistant tumour cell lines of the colon, such as DLD-I and SW480, as well as on other tumour cell lines of the lung and ovary. In particular, all cell lines, object of the analysis, were related to tumours of epithelial type.

[0023] Preliminarily, cell lines HCT116p53KO, DLD-I and SW480 were treated with common chemotherapeutic drugs in order to confirm their resistance to the drug-induced apoptosis. The chemotherapeutic drugs usable in accordance

with the present invention can be of any type suitable for inducing the apoptosis process in the affected tumour cells, such as for example an antimetabolite or any DNA-damaging agent comprising the inhibitors of the topoisomerase I, inhibitors of the topoisomerase II, the platinum coordination compounds and alkylating agents.

[0024] The aforesaid preliminary tests have shown how, after treatment for 72 hours in 200 μ M 5FU, the cell mortality was less than 10%, against a wt HCR1 16 cell mortality of greater than 95%.

[0025] Supplementary tests of colony forming assays (CFA), have moreover demonstrated how such drug resistance was of non-transitory type.

[0026] Once the resistance to apoptosis induced by chemotherapeutic drugs was confirmed, 200xIO6 HCT116p53KO cells were infected with the above-identified pRetroSuper library, provided by the Bernards laboratories. Each vector of this library was advantageously equipped with a selection cassette for a puromycin resistance gene, so that it was possible to select the HCT116p53KO cells actually infected by the vectors of the library through treatment with puromycin (2mg/l in the culture medium for two days).

[0027] At the end of the antibiotic treatment, the still-living cells were then collected, which therefore comprised all of the cells infected by the retroviruses of the library whose silenced genes were not incompatible with the cellular survival.

[0028] The cells thus collected were then treated with 200 μ M 5FU for 72 hours, while at the same time wt HCT116 cells and uninfected HCT116p53KO cells were also subjected to the same treatment, as controls.

[0029] At the end of the treatment, it was found that about half of the cells were floating in the culture medium, therefore dead. Such cells represented the sought-after phenotype, so that they were collected and subjected to the necessary treatment for the identification of the genes silenced by the retroviral library.

[0030] In brief, such treatments comprised of the extraction of the DNA and the amplification by means of PCR (Polymerase Chain Reaction) of a region of 643 base pairs containing the region H1 of a specific promoter and the adjacent region coding the nucleotide sequence of interest. PCR amplification was performed using a pRS-fw primer: 5'-CCCTTGAACCTCCTC GTTCGACC-3' (SEQ ID NO: 3) and pRS-rev primer: 5'-GAGACGTGCTACTTCCATTTGTC-B' (SEQ ID NO: 4). The products obtained by the amplification were then bound in pRS retroviral vectors and the infection process of HCT116p53KO cells was completely repeated with the new vectors, so as to refine the screening. The products were digested with EcoRI/XhoI and recloned into pRS.

[0031] The products obtained from the second amplification treatment with PCR on the DNA harvested from the dead cells after new treatment with 5FU were newly isolated and bound in retroviral vectors pRS and then used for transforming DH5alpha bacteria whose respective plasmids were sequenced for the identification of the genes which gave rise to the phenotypic expression of interest.

[0032] Once the single genes were obtained and identified whose silencing by means of interference with RNA gave rise to the reversion of the resistance of the tumour cells tested to the 5FU, the separated and independent validation of the single genes took place. Firstly, the validation was carried out in vitro on HCT116p53KO tumour cell samples, each of which separately infected with one of the previously-made plasmids, so as to silence in a specific and stable manner one of the genes indicated by the preceding screening and verify its capacity to modulate the resistance to drugs. The samples were then selected with puromycin, placed in Petri dishes at 50% confluence and treated with 200 μ M of 5FU for 12 hours.

[0033] The evaluation of the reversion of the drug resistance was carried out by means of observation of the formation of colonies according to the protocol defined by the CFA and their comparison with a wt HCT1 16 sample and an uninfected HCT116p53KO sample.

[0034] In figure 1, the results are reported in graph form which were obtained from this first in vitro validation. As clearly shown by the graph, a high percentage of identified genes are capable, when functionally blocked, of consistently reverting the colony forming ability of 5FU-treated HCT116p53KO cells. HCT116 and KO represent positive and negative controls.

[0035] This first validation has in particular permitted identifying a group of genes whose specific silencing has given rise to a 5FU-induced inhibition of the growth of the tumour colonies greater than 50% with respect to the HCT116p53KO sample.

[0036] These genes, themselves known and characterised, are listed below with their official symbol together with their identification number (between parentheses) reported on the NCBI Entrez Gene data bank:

EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), RAMP2 (10266), RAMP3 (10268), CLRN1 (7401), MAPK4 (5596), PIK3C2A (5286), PIK3CG (5294), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), JAK1 (3716), CHEK1 (1111), PIM1 (5292), TRB3 (57761), BTG1 (694), LATS1 (9113), LIMK2 (3985), MYLK (4638), PAK1 (5058), PAK2 (5062), CDC2 (983), BTK (695), PNRC2 (55629), NCOA4 (8031), NR2C1 (7181), TPR (7185), RBBP8 (5932), TRPC7 (57113), FXYD1 (5348), ERN1 (2081), PRSS16 (10279), RPS3 (6188), CCL23 (6368) and SERPINE1 (5054).

[0037] Among the above-listed genes, a first subgroup is also identifiable of genes whose silencing advantageously

EP 2 546 651 A1

leads to an over 75% inhibition of the tumour cells growth. Such first subgroup is formed by the following genes:

EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), RAMP2 (10266), RAMP3 (10268), MAPK4 (5596), PIK3C2A (5286), PIK3CG (5294), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), JAK1 (3716), CHEK1 (1111), PIM1 (5292), TRB3 (57761), BTG1 (694), LATS1 (9113), LIMK2 (3985), BTK (695), PNRC2 (55629), NCOA4 (8031), NR2C1 (7181), TPR (7185), TRPC7 (57113), FXYD1 (5348), ERN1 (2081), RPS3 (6188) and SERPINE1 (5054).

[0038] In a more advantageous manner, a second subgroup was further identified of genes whose silencing advantageously leads to an over 95% inhibition of the growth of the tumour cells. Such subgroup is formed by the following genes:

EphA1 (2041), EphA2 (1969), EphA8 (2046), RAMP3 (10268), PIK3C2A (5286), GSK3beta (2932), IRAK3 (11213), DAPK1 (1612), CHEK1 (1111), PIM1 (5292), BTK (695), NCOA4 (8031), TPR (7185).

[0039] The gene GSKalpha (2931), isoform of the gene GSK3beta, must be added to the above-listed genes; in separate tests whose results are shown by the graphs of figures 2a and 2b it has shown an optimal efficiency in the reversion of the resistance both to 5FU and to the oxaliplatin in HCT116p53KO cells, entirely comparable to its beta isoform. In detail, figure 2a compares the percentages of cell deaths in the absence (symbol "-") and presence (symbol "+") of 200 μ M 5FU (72 hr treatment) upon wild type (wt) HCT116 cells, HCT116p53KO drug resistant cells, GSK3alpha and GSK3beta silenced gene cells. In comparison to the HCT116p53KO drug resistant cells, HCT116p53KO cells with GSK3alpha and GSK3beta genes silenced resulted in a high percentage of tumour cell death in the presence of 5FU. Figure 2b compares the percentages of cell deaths in the absence (symbol "-") and presence (symbol "+") of 50 μ M oxaliplatin (72 hr treatment) upon wt HCT116 cells, HCT116p53KO drug resistant cells, GSK3alpha and GSK3beta silenced gene cells. In comparison to the HCT116p53KO drug resistant cells, HCT116p53KO cells with GSK3alpha and GSK3beta genes silenced also resulted in a high percentage of tumour cell death in the presence of oxaliplatin.

[0040] The formal confirmation of the silencing of the specific genes by means of interference was carried out through Western Blot analysis of the levels of the protein coded by them, if the antibody was commercially available (EphA1, EphA2, CSF1R, VEGFR, GSK3, JAK1, CHEK1, LIMK2, CDC2, BTK). Western Blot analysis was performed by lysing the puromycin-selected cells in E1A buffer (50 mM HEPES pH 8; 500 mM NaCl; 0.1% NP 40; DTT IM;

[0041] EDTA IMm). 8-12% SDS-polyacrylamide gel electrophoresis was used to separate 30 μ g of protein, which was later transferred to polyvinylidene difluoride membranes. Antibodies were then used to probe the Western Blots.

[0042] The effectiveness of the plasmids capable of silencing the genes belonging to the above-identified group was further tested on DLD-I and SW480, other tumour cell lines of the colon known for possessing mutated p53 and for their resistance to drugs.

[0043] The capacity to diminish the resistance to chemotherapeutic drugs was generally confirmed, even with different performances. In particular, the inhibition percentage of the growth of colonies after drug treatment over all three cell lines was optimal when the following genes were silenced :

EphA1 (2041), EphA2 (1969), EphA8 (2046), EphB2 (2048), CSF1R (1436), VEGFR2 (3791), PIK3C2A (5286), PIK3CG (5294), GSK3alpha (2931), GSK3beta (2932), IRAK3 (11213), CDC2 (983), CHEK1 (1111), LATS1 (9113), TRB3 (57761), JAK1 (3716), BTK (695), PIM1 (5292), LIMK2 (3985), PAK2 (5062).

EXAMPLE 2

[0044] As an example, in figures 3a-3c graphs are reported following silencing tests of the gene GSK3beta in the three tested tumour cell lines, in which the fraction of dead cells after the treatment with 5FU in samples infected with vectors capable of silencing the aforesaid gene is reported and compared with samples infected with empty vectors. In detail, figure 3a compares the percentages of cell deaths in the absence (symbol "-") and presence (symbol "+") of 200 μ M 5FU (72 hr treatment) upon wt HCT116 cells, HCT116p53KO drug resistant cells, and GSK3beta silenced gene cells. In comparison to the HCT116p53KO drug resistant cells, HCT116p53KO cells with GSK3beta gene silenced resulted in a high percentage of tumour cell death in the presence of 5FU. Figure 3b compares the percentages of cell deaths in the absence (symbol "-") and presence (symbol "+") of 200 μ M 5FU (72 hr treatment) upon wt DLD-I cells and GSK3beta silenced gene DLD-I cells. In comparison to the wt DLD-I cells, GSK3beta silenced gene DLD-I cells resulted in a high percentage of tumour cell death in the presence of 5FU. Figure 3c compares the percentages of cell deaths in the absence (symbol "-") and presence (symbol "+") of 200 μ M 5FU (72 hr treatment) upon wt SW480 cells and GSK3beta silenced gene SW480 cells. In comparison to the wt SW480 cells, GSK3beta silenced gene SW480 cells resulted in a high percentage of tumour cell death in the presence of 5FU.

[0045] In addition to 5FU, representative example of the family of chemotherapeutic drugs of the antimetabolic type,

the reversion of the resistance to drugs was also tested on chemotherapeutic drugs of different types, such as oxaliplatin.

[0046] In figure 4a, the fractions of dead cells induced by a treatment with oxaliplatin (50 μ M) are reported in samples of colon tumour cell lines DLD-I and SW480, respectively infected with empty vectors and with vectors silencing the gene GSK3beta.

[0047] The substantial diminution of the resistance to the apoptosis induced by oxaliplatin in the sample in which GSK3beta was silenced is evident. In figure 4b, a graph is reported in which the results of an analogous test are indicated on the cell line SW480, in which the drug used was a combination of 5FU and oxaliplatin.

[0048] As mentioned previously and shown in figures 2a and 2b, GSK3alpha silencing has the same effect as GSK3beta in modulating the apoptotic response to 5FU and oxaliplatin.


[0049] Further study was conducted to determine if 5FU-induced cell death in the absence of GSK3 was cytochrome C-dependent or independent. Utilizing anti-cytochrome C and DAPI staining, as shown in figure 5, it was found that 5FU-induced cell death in the absence of GSK3 is cytochrome C-independent. More specifically, utilizing anti-AIF and DAPI staining, as shown in figure 7, it was discovered that in the absence of GSK3, AIF translocates to the nucleus resulting in cell death. This was further supported by the finding that caspases 3 and 7 were not activated during 5FU-induced cell death in GSK3 silenced cells, as shown in figure 6.

EXAMPLE 3

[0050] Another particularly representative example of the above-identified gene group is constituted by the gene BTK, on which several investigations were undertaken.

[0051] BTK kinase is a cytoplasmic protein tyrosine kinase crucial for B-cell development and differentiation. BTK mutation is infact responsible for X-linked agammaglobulinemia (XLA), a primary immunodeficiency mainly characterized by lack of mature B cells as well as low levels of immunoglobulins. In B cells BTK has been reported as having either pro-apoptotic or anti-apoptotic functions. Moreover, BTK has been so far assumed as being expressed only in some bone marrow-derived lineages such as B and mast cells, erythroid progenitors, platelets. Our finding that BTK is a gene whose silencing reverts resistance to the cytotoxic action of 5FU demonstrated for the first time that BTK is expressed also in cell types others than cells of the hematopoietic lineage. Firstly, the effectiveness was tested of the reversion of the resistance to drugs in HCT116p53KO tumour cells treated with an inhibitor compound of the protein BTK, such to demonstrate how the functional blocking of the gene of interest can be carried out in alternative ways to the silencing by means of RNAi.

[0052] The compound employed in these tests was (2Z)-2-cyan-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide, known as LFM-A13, whose structural formula is reported below in Formula 1.



Formula 1

[0053] In figure 8, the results of the comparison test are reported in a graph of the functional blocking of the BTK gene by means of plasmids, siRNA or LFM- A13 in samples of HCT116p53KO cells treated with 5FU. It can be easily noted how the obtained level of reversion to the drug resistance, expressed by means of the percentage fraction of dead cells, is entirely comparable. In detail, figure 8 compares the percentages of cell deaths in the presence of 200 μ M 5FU (72 hr treatment) upon wt HCT116 cells and HCT116p53KO drug resistant cells with or without (symbol "empty" and "-") specific depletions of BTK following transient siRNA transfection (symbol "BTKi"), stable retroviral-mediated RNA interference (symbol "shBTK"), and using LFMA13, an inhibitor compound of BTK. According to the protective effect of BTK revealed by the above described inhibition experiments, BTK overexpression protects sensitive HCT1 16 wt from 5FU-induced cell death. In detail, Fig. 9 compares the percentages of cell deaths in the presence of 200 μ M 5FU (72 hr treatment) upon wt HCT116 cells infected with empty pBabe vector, wt HCT1 16 cells infected with pBabe BTK vector and HCT116p53KO drug resistant cells.

[0054] It was also determined that BTK inhibition reverts resistance also to oxaliplatin (figure 10a) and in DLD-I (figure 10b).

[0055] The diminution of the resistance to chemotherapeutic drugs following the functional blocking of the gene BTK by means of LFM-A13 was further confirmed by tests conducted in vitro on epithelial tumour cell lines different from those of the colon. In figure 11 levels of BTK have been investigated, by means of Western blot, in several different epithelial carcinoma cell lines showing that the kinase is expressed in most of them. In particular, in figures 12a and 12b, graphs were reported of the reversion tests obtained on SKOV cell lines (related to an ovarian tumour) and A549 cell lines (related to a lung tumour).

[0056] In detail, figure 12a compares the percentages of cell deaths in the absence (symbol "NT" and "-") and presence of 200 μ M 5FU, 50 μ M OxPt, and the combination of the two upon resistant ovarian (SKOV) cells with or without BTK inhibition through the usage of LMFA13. In comparison to the SKOV cells without LMFA13, the SKOV cells with LMFA13 resulted in a high percentage of tumour cell death. Figure 12b compares the percentages of cell deaths in the absence (symbol "NT" and "-") and presence of 200 μ M 5FU, 50 μ M OxPt, and the combination of the two upon resistant lung (A549) cells with or without BTK inhibition through the usage of LMFA13. In comparison to the A549 cells without LMFA13, the A549 cells with LMFA13 resulted in a high percentage of tumour cell death.

[0057] In both cases, it is noted how the treatment of the cell lines with LFM-A13, functional inhibitor of the BTK gene, leads to a considerable increase of the cellular mortality after exposure to 5FU or oxaliplatin or both drugs in combination.

[0058] Moreover, the high effectiveness of the action of diminution of the drug-resistance also in these cell lines, confirms that the validity of the results obtained in the preceding tests can be extended at least to all types of epithelial tumour, such as lung tumour, ovarian tumour and breast tumour. The optimal results pointed out above have suggested validating the gene BTK also through ex-vivo analysis on epithelial human tumour samples.

[0059] Firstly, it was verified through Western Blot that the BTK protein levels were high in 30% of the samples of ovarian tumour cells drawn from patients in advanced stage of disease and/or resistant to chemotherapeutic drugs.

[0060] Secondly, examinations were conducted on colon tumour stem cells isolated from patients in order to verify if the investigated genes were expressed (and in what measure) also in this cell type. In fact, according to recent studies (Dean et al., 2005), these stem cells would be the responsible principals of the drug resistance.

[0061] In all four tumour stem cell lines analysed, isolated from different patients, the expression of the protein BTK is very high, at least 4-5 times greater than the expression detected on the colon carcinoma cell lines used in the functional experiments, suggesting that the determination of the BTK levels can advantageously be used as a method for defining the stem cell properties of the tumour cells examined, and consequently also their resistance to chemotherapeutic drugs.

[0062] The results have shown that BTK levels determine the sensitivity of tumor cells to 5FU and that BTK inhibition reverses drug-resistance. Anti-cytochrome C immunostaining in 5FU-treated cells (figure 13) showed cytoplasmic accumulation after 5FU treatment in resistant cells only when BTK was inhibited, supporting the finding that reversal of drug-resistance upon BTK inhibition is due to activation of apoptosis. The same finding is also supported by the graph reported in Figure 14, evaluating the level of caspase 3/7 activation upon 5FU treatment in HCT116p53KO resistant cells in the presence or in the absence of BTK inhibitor LFM-A13. High levels of caspase 3/7 activation, measured by means of a luminometric assay as RLU/number of cells, are observed in 5FU-treated HCT116p53KO cells only when BTK is inhibited.

[0063] The predicted and reported molecular weight of BTK protein is 77 kDa. The protein identified in western blot as BTK by a specific antibody (sc-1696, from Santa Cruz Biotechnology) in HCT116p53KO and in all other epithelial carcinoma cell lines tested (6 breast cell lines, 3 ovary cell lines, 7 lung cell lines, 5 colon cell lines), in contrast, has an apparent molecular weight around 65-68 kDa (figure 11, figure 15a) suggesting that in epithelial cell lines a shorter BTK isoform is expressed.

[0064] To confirm these results an immunoprecipitation analysis was carried out using two different and specific BTK antibodies (the above cited sc-1696 and BL7, kind gift of Dr. Mike Tomlinson, University of Birmingham, UK). The results in figure 15b show that only this novel isoform is expressed in epithelial cell lines whereas in a leukemic cell line (Nalm β), already known from the literature to express the classical 77 kDa form, both isoforms are present.

[0065] Therefore, a bioinformatic analysis of BTK coding sequence (cds) has been carried out and, accordingly, a second nucleotide triplet ATG (nt 428-430), in frame with the one known to be used to translate BTK (nt 164-166) and susceptible to start the translation of a protein has been identified. The expected molecular weight of the putative protein translated starting from this second ATG is 67 kDa, consistent with the apparent molecular weight of the band identified by different BTK antibodies in epithelial carcinoma cells. In order to identify which portion is missing in the mRNA coding for the shorter and novel isoform of the BTK protein, PCR experiments using different primers pairs (annealing at different parts of the cds as indicated in the upper diagram of figure 16) have been performed. As shown in figure 16, these experiments indicate that the 5' end, upstream of nucleotide 202, is absent or different in HCT116p53KO cells.

[0066] 5'RACE/sequencing experiments have been performed on mRNA from HCT116p53KO cells in order to determine the identity of the unknown 5' end. Subsequently, alignment analysis between the cDNA derived from mRNA from HCT116p53KO cells and the cDNA deriving from the standard BTK mRNA, identified by GenBank accession #NM_00061, using ClustalW computer program (results shown in figure 17) demonstrated that the sequence upstream of the second exon (starting at nt 134 of the cds) is different from what reported in literature, i.e epithelial colon carcinoma cells

express a different first exon.

5 [0067] BLAST analysis using a genomic database (figure 18) localize the first exon of NM_000061 BTK transcript at 101160K on the chromosome X contig, in correspondence with the beginning of BTK locus. At variance, the first exon of the novel BTK transcript aligns 15192 bp 5' of the first known BTK exon, immediately downstream of the RPL36A locus, suggesting that it corresponds to a hitherto unrecognized BTK exon. Moreover, this novel exon is present in HCT116p53KO instead of the first "classical" exon suggesting that this is an "alternative" first exon, whose usage gives rise to a different BTK mRNA, transcribed in cells expressing this shorter BTK isoform.

10 [0068] PCR/sequencing experiments demonstrated the expression of this "alternative" BTK mRNA not only in all coloncarcinoma cell lines tested (HCT116p53KO, DLD-I and SW480) but also in 9/9 FFPE-samples from colon carcinoma patients (figure 19).

15 [0069] It should be noted that the first exon of BTK, as identified by GenBank accession # NM_000061, corresponds to the 5'UTR of the mRNA, being the ATG triplet encoding the first Met amino acid of BTK protein located in the second exon. 5'UTRs usually perform regulatory functions such as directing cap-dependent or IRES-mediated cap-independent translation. A different first exon, as identified in the novel transcript, can therefore dictate whether a different ATG (in this case an ATG located in the 4th exon) has to be used to start the translation of BTK protein, and therefore regulate the expression of different isoforms.

[0070] The nucleotide sequence of the first exon corresponding to the 5'UTR of the novel mRNA expressed by the BTK gene is reported in SEQ ID NO: 1, attached to the present description.

20 [0071] The amino acid sequence of the novel isoform of BTK protein coded by the novel transcript is reported in SEQ ID NO: 2, attached to the present description.

[0072] The above results suggest a method for determining the resistance of tumour cells to chemotherapeutic drugs as well as a method for the identification of the presence of tumour stem cells, wherein the expression of gene BTK comprises the steps of verifying the presence of the novel isoform of the BTK protein.

25 [0073] The presence of the novel isoform of the BTK protein may be controlled verifying the presence of the protein, for instance using western blot or immunoprecipitation or immunochemistry or immunofluorescence analysis, or, preferably, verifying the presence of the mRNA having the alternative first exon, whose cDNA shows the nucleotide sequence defined in SEQ ID NO: 1. The latter may be advantageously carried out by means of PCR analysis, preferably using primers having a sequence included in SEQ ID NO: 1.

30 [0074] This new method is expected to show relevant advantages, whit respect to the known prior art, particularly when used for analysing tumoral tissues taken from human patients. Actually, it is well known that tumoral tissues taken from human patients may contain an effective amount of lymphocytes which may also express BTK protein, thus disturbing the search of BTK protein expressed by the tumoral cells.

35 [0075] However, BTK protein expressed by lymphocytes is the "classical" isoform of BTK protein having a molecular weight of 77 KDa, so that the search of the novel isoform of BTK protein may be carried out without any interference, with a simple PCR analysis looking for the presence of BTK mRNA having the alternative first exon.

40 [0076] The present invention therefore resolves the above-lamented problem with reference to the mentioned prior art, offering at the same time numerous other advantages, including making possible the development of diagnostic methods capable of predicting the therapeutic response so to refine not only the diagnostics but above all direct the best therapeutic choice.

EP 2 546 651 A1

SEQUENCE LISTING

<110> BIONSIL S.R.L.

5 <120> Modulator compounds of the drug resistance in epithelial tumour cells

<130> 10342PTEP/DIV 1

<150> ITPD2007A000088
 <151> 2007-03-14
 10 <150> EP07106119.6
 <151> 2007-04-13

<160> 4

<170> BiSSAP 1.0

15 <210> 1
 <211> 300
 <212> DNA
 <213> Homo sapiens

20 <220>
 <221> source
 <222> 1..300
 <223> /mol_type="DNA"
 /organism="Homo sapiens"

25 <400> 1
 ttttgggtgga ctctgctacg tagtggcggt cagtgaaggg agcagtggtt ttcccagatc 60
 ctctggcctc cccgtccccg agggaagcca ggactagggt cgaatgaagg ggtcctccac 120
 30 ctccacgttc cattcctggt ccacctcaag gtcactggga acacctttcg cagcaaactg 180
 ctaattcaat gaagacctgg agggagccaa ttgttccagt tcatctatca catggccagt 240
 tgggccattc aacaaatggt tattggatgc ccattatgtg gcaggcactg ttccggggga 300

35 <210> 2
 <211> 571
 <212> PRT
 <213> Homo sapiens

40 <220>
 <221> SOURCE
 <222> 1..571
 <223> /mol_type="protein"
 /organism="Homo sapiens"

45 <400> 2
 Met Glu Gln Ile Ser Ile Ile Glu Arg Phe Pro Tyr Pro Phe Gln Val
 1 5 10 15
 Val Tyr Asp Glu Gly Pro Leu Tyr Val Phe Ser Pro Thr Glu Glu Leu
 20 25 30
 50 Arg Lys Arg Trp Ile His Gln Leu Lys Asn Val Ile Arg Tyr Asn Ser
 35 40 45
 Asp Leu Val Gln Lys Tyr His Pro Cys Phe Trp Ile Asp Gly Gln Tyr
 50 55 60
 Leu Cys Cys Ser Gln Thr Ala Lys Asn Ala Met Gly Cys Gln Ile Leu
 65 70 75 80
 55 Glu Asn Arg Asn Gly Ser Leu Lys Pro Gly Ser Ser His Arg Lys Thr
 85 90 95
 Lys Lys Pro Leu Pro Pro Thr Pro Glu Glu Asp Gln Ile Leu Lys Lys

EP 2 546 651 A1

100 105 110
 Pro Leu Pro Pro Glu Pro Ala Ala Ala Pro Val Ser Thr Ser Glu Leu
 115 120 125
 Lys Lys Val Val Ala Leu Tyr Asp Tyr Met Pro Met Asn Ala Asn Asp
 130 135 140
 Leu Gln Leu Arg Lys Gly Asp Glu Tyr Phe Ile Leu Glu Glu Ser Asn
 145 150 155 160
 Leu Pro Trp Trp Arg Ala Arg Asp Lys Asn Gly Gln Glu Gly Tyr Ile
 165 170 175
 Pro Ser Asn Tyr Val Thr Glu Ala Glu Asp Ser Ile Glu Met Tyr Glu
 180 185 190
 Trp Tyr Ser Lys His Met Thr Arg Ser Gln Ala Glu Gln Leu Leu Lys
 195 200 205
 Gln Glu Gly Lys Glu Gly Gly Phe Ile Val Arg Asp Ser Ser Lys Ala
 210 215 220
 Gly Lys Tyr Thr Val Ser Val Phe Ala Lys Ser Thr Gly Asp Pro Gln
 225 230 235 240
 Gly Val Ile Arg His Tyr Val Val Cys Ser Thr Pro Gln Ser Gln Tyr
 245 250 255
 Tyr Leu Ala Glu Lys His Leu Phe Ser Thr Ile Pro Glu Leu Ile Asn
 260 265 270
 Tyr His Gln His Asn Ser Ala Gly Leu Ile Ser Arg Leu Lys Tyr Pro
 275 280 285
 Val Ser Gln Gln Asn Lys Asn Ala Pro Ser Thr Ala Gly Leu Gly Tyr
 290 295 300
 Gly Ser Trp Glu Ile Asp Pro Lys Asp Leu Thr Phe Leu Lys Glu Leu
 305 310 315 320
 Gly Thr Gly Gln Phe Gly Val Val Lys Tyr Gly Lys Trp Arg Gly Gln
 325 330 335
 Tyr Asp Val Ala Ile Lys Met Ile Lys Glu Gly Ser Met Ser Glu Asp
 340 345 350
 Glu Phe Ile Glu Glu Ala Lys Val Met Met Asn Leu Ser His Glu Lys
 355 360 365
 Leu Val Gln Leu Tyr Gly Val Cys Thr Lys Gln Arg Pro Ile Phe Ile
 370 375 380
 Ile Thr Glu Tyr Met Ala Asn Gly Cys Leu Leu Asn Tyr Leu Arg Glu
 385 390 395 400
 Met Arg His Arg Phe Gln Thr Gln Gln Leu Leu Glu Met Cys Lys Asp
 405 410 415
 Val Cys Glu Ala Met Glu Tyr Leu Glu Ser Lys Gln Phe Leu His Arg
 420 425 430
 Asp Leu Ala Ala Arg Asn Cys Leu Val Asn Asp Gln Gly Val Val Lys
 435 440 445
 Val Ser Asp Phe Gly Leu Ser Arg Tyr Val Leu Asp Asp Glu Tyr Thr
 450 455 460
 Ser Ser Val Gly Ser Lys Phe Pro Val Arg Trp Ser Pro Pro Glu Val
 465 470 475 480
 Leu Met Tyr Ser Lys Phe Ser Ser Lys Ser Asp Ile Trp Ala Phe Gly
 485 490 495
 Val Leu Met Trp Glu Ile Tyr Ser Leu Gly Lys Met Pro Tyr Glu Arg
 500 505 510
 Phe Thr Asn Ser Glu Thr Ala Glu His Ile Ala Gln Gly Leu Arg Leu
 515 520 525
 Tyr Arg Pro His Leu Ala Ser Glu Lys Val Tyr Thr Ile Met Tyr Ser
 530 535 540
 Cys Trp His Glu Lys Ala Asp Glu Arg Pro Thr Phe Lys Ile Leu Leu
 545 550 555 560
 Ser Asn Ile Leu Asp Val Met Asp Glu Glu Ser
 565 570

<210> 3
 <211> 23
 <212> DNA
 <213> Homo sapiens

<220>
 <221> SOURCE
 <222> 1..23
 <223> /mol_type="DNA"
 /organism="Homo sapiens"

<400> 3
 cccttgaacc tcctcgttcg acc 23

<210> 4
 <211> 23
 <212> DNA
 <213> Homo sapiens

<220>
 <221> source
 <222> 1..23
 <223> /mol_type="DNA"
 /organism="Homo sapiens"

<400> 4
 gagacgtgct acttccattt gtc 23

Claims

1. A method for predicting the resistance of a tumour cell to chemotherapeutic drugs comprising the step of:
 - a. measuring the level of expression of the mRNA and/or the isolated active protein and/or both of a GSK3 gene, wherein the GSK3 gene is chosen from the group consisting of either GSK3alpha isoform or GSK3beta isoform.
2. A method for predicting the reversal of resistance of a tumour cell to chemotherapeutic drugs, comprising the steps of:
 - a. predicting the resistance of tumour cells to chemotherapeutic drugs according to claim 1;
 - b. functionally and selectively blocking the GSK3 gene; and
 - c. testing the percentage of tumour cell death in the presence of chemotherapeutic drug, wherein an increase in the percentage of tumour cell death allows to predict the reversal of resistance of tumour cells to chemotherapeutic drugs.
3. A method for reverting the resistance of a tumour cell to chemotherapeutic drugs, comprising the steps of:
 - a. predicting the resistance of tumour cells to chemotherapeutic drugs according to claim 1;
 - b. functionally and selectively blocking the GSK3 gene; and
 - c. contacting the tumour cells with a therapeutically effective amount of at least one chemotherapeutic drug.
4. The method according to anyone of claims 2 or 3, wherein step b. of functionally and selectively blocking the GSK3 gene is carried out by administering to the tumour cells a therapeutically effective amount of a composition comprising a small interfering RNA (siRNA) or a small hairpin RNA (shRNA).
5. The method according to claim 1, wherein the measurement of GSK3 expression allows to identify the presence of tumour cells.
6. The method according to anyone of claims 1-5, wherein the tumour cells are of epithelial type.
7. The method according to anyone of claims 1-6, wherein the tumour cells are chosen from the group consisting of colon, lung, or ovary tumour cells.

EP 2 546 651 A1

8. The method according to anyone of claims 1-7, wherein the tumour cells are stem cells.

9. The method according to anyone of claims 1-8, wherein the chemotherapeutic drug is an anti-metabolite agent.

5 10. The method according to anyone of claims 1-8, wherein the chemotherapeutic drug is a DNA-damaging agent selected from the group consisting of a topoisomerase I inhibitor, a topoisomerase II inhibitor, a platinum coordination compound, an alkylating agent, and a combination thereof.

10 11. The method according to claims 10, wherein the chemotherapeutic drug is chosen from the group consisting of 5-fluorouracil, oxaliplatin, or a mixture thereof.

12. A diagnostic kit for predicting the resistance of tumour cells to chemotherapeutic drugs in the method of claim 1, comprising primers and/or probes and/or antibodies for measuring the level of expression and/or activation of a GSK3 gene and/or protein.

15 13. The kit according to claim 12, additionally comprising a compound capable of functionally and selectively blocking the GSK3 gene and/or protein.

20 14. The kit according to claim 13, wherein said compound capable of functionally and selectively blocking the GSK3 gene is a small interfering RNA (siRNA) or a small hairpin RNA (shRNA).

25 15. The diagnostic kit according to anyone of claims 11-14, wherein the GSK3 gene and/or protein is chosen from the group consisting of the GSK3alpha or the GSK3beta isoform.

30

35

40

45

50

55




Fig. 1




Fig. 2a




Fig. 2b




Fig. 3a

Fig. 3b

Fig. 3c




Fig. 4a

Fig. 4b




Fig. 13




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10a





Fig. 10b

Fig. 11






Fig. 12a




Fig. 12b






Fig. 14



CLUSTAL 2.0.3 multiple sequence alignment

```

NM_000061
alternative
-----
TTTTGGTGGACTCTGCTACGTTAGTGGCGTTTCAGTGAAGGGAGCAGTGTITTTTCCCAGATC 60

NM_000061
alternative
-----
CTCTGGCC?CCCCGTCCCCGAGGGAGCCAGGACTAGGGT?CGAATGAAGGGGTCCCTCCAC 120

NM_000061
alternative
-----CTCAGACTG 9
CTCCACGTTCCATTCCTGTTCACCTCAAGGTCACCTGGGAACACCTTTCGCAGCNAACTG 180
** ****


NM_000061
alternative
TCCTTCTCTCTGGACTGTAAGAATATGTCTCCAGGGCCAGT--GTCTGCTGCG-ATCGA 66
--CTAATTCANTGAAGACCTGGAGGGAGCCANTTGTTCAGTTCATCTATCAGATGGCCA 238
** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

NM_000061
alternative
GTCCACCTTCCAAAGTCC?GGCATT?CAATGCR?CTGGGAAGCTACCTGCRITTAAGTCAG 126
GTGGTCCATTCACCAAATGGTTAT?GGATGC--CCATTATGTGGCAGGCACTGTTCGG 296
** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

NM_000061
alternative
GACTGAGCACACAGGTGAAGTCCAGAAAGAAAGAGCTATGGCCGAGTGAATCTGGAGAG 186
GGGAGGCACACAGGTGAAGTCCAGAAAGAAAGAGCTATGGCCGAGTGAATCTGGAGAG 356
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
    
```

Fig. 17

Blast exons 1-5 NM_000061 vs genomic



Blast exons 1-5 alternative BTK trascript vs genomic




Fig.18




Fig. 19



EUROPEAN SEARCH REPORT

Application Number
EP 12 17 9806

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2006/063164 A (WISCONSIN ALUMNI RES FOUND [US]; KUNNIMALAIYAAN MUTHUSAMY [US]; CHEN H) 15 June 2006 (2006-06-15) * paragraphs [0008], [0015], [0139], [0140]; table 1 *	1-12, 15	INV. G01N33/50 A61P35/00 C12Q1/68 C12N15/113 C12N15/11
X	DE TONI F ET AL: "A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia", ONCOGENE, vol. 25, no. 22, May 2006 (2006-05), pages 3113-3122, XP002502049, ISSN: 0950-9232 * abstract; figures 1, 3, 3b *	12-15	
X	WO 2006/006939 A1 (AGENCY SCIENCE TECH & RES [SG]; YU QIANG [SG]) 19 January 2006 (2006-01-19) * paragraphs [0008], [0107], [0108], [0112], [0101]; figure 5; example 1 *	12, 15	TECHNICAL FIELDS SEARCHED (IPC)
X	TAN JING ET AL: "Pharmacologic modulation of glycogen synthase kinase-3 beta promotes p53-dependent apoptosis through a direct bax-mediated mitochondrial pathway in colorectal cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 19, 1 October 2005 (2005-10-01), pages 9012-9020, XP008096562, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-1226 * page 9013, left column, paragraph 3 *	12, 15	A61K C12N G01N C12Q
----- -/--			
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 6 December 2012	Examiner Habedanck, Robert
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03 02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 12 17 9806

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	BEUREL E ET AL: "GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/AP0-1) expression", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 300, no. 2, 1 November 2004 (2004-11-01), pages 354-364, XP004592423, ISSN: 0014-4827, DOI: 10.1016/J.YEXCR.2004.08.001 * abstract *	1-15	
A	"83 Dual effects of GSK-3beta inhibition on death receptor-mediated apoptosis in hepatoma cells", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 42, 1 April 2005 (2005-04-01), page 35, XP027780548, ISSN: 0168-8278 [retrieved on 2005-04-01] * abstract *	1-15	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search Munich		Date of completion of the search 6 December 2012	Examiner Habedanck, Robert
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

1
EPO FORM 1503 03.82 (F04/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 12 17 9806

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

06-12-2012

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2006063164 A	15-06-2006	-----	-----
WO 2006006939 A1	19-01-2006	AU 2005262925 A1	19-01-2006
		CA 2569091 A1	19-01-2006
		CN 1980681 A	13-06-2007
		EP 1768679 A1	04-04-2007
		JP 5033624 B2	26-09-2012
		JP 2008505890 A	28-02-2008
		US 2011293746 A1	01-12-2011
		WO 2006006939 A1	19-01-2006
		-----	-----

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **BERNS et al.** *NATURE*, 25 March 2004, vol. 428
[0021]